Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 17/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17873646 | 1.00 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL19753585 | 0.89 | OPRK1 (0.80) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL5629451 | 0.88 | OPRK1 (0.79) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL5631745 | 0.86 | OPRK1 (0.76) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL6478689 | 0.86 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL6478692 | 0.86 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL17873667 | 0.85 | OPRK1 (1.00) | OPRK1CYP2D6 | |
| SCHEMBL17873664 | 0.85 | OPRK1 (1.00) | OPRK1CYP2D6 | |
| SCHEMBL5629426 | 0.85 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL9510585 | 0.85 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11241415-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the κ opioid receptor | NEKTAR THERAPEUTICS (US) | 2022-02-08 | — | — | US | disclosed |
| US-11241415-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the κ opioid receptor | NEKTAR THERAPEUTICS (US) | 2022-02-08 | — | — | US | disclosed |
| US-20190269652-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS | 2019-09-05 | — | — | US | disclosed |
| US-20190269652-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS | 2019-09-05 | — | — | US | disclosed |
| EP-3237388-B1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS (US) | 2019-07-03 | — | — | EP | disclosed |
| US-10322107-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor | NEKTAR THERAPEUTICS (US) | 2019-06-18 | — | — | US | disclosed |
| US-10322107-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor | NEKTAR THERAPEUTICS (US) | 2019-06-18 | — | — | US | disclosed |
| US-20170368029-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS | 2017-12-28 | — | — | US | disclosed |
| EP-3237388-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | Nektar Therapeutics (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016106133-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106133-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | NEKTAR THERAPEUTICS (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368029-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | OPRK1, OPRM1, OPRD1 | OPRK1 1/4885CYP2D6 513/4885CYP3A4 462/4885 |
| US-20190269652-A1 | N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE DERIVATIVES AGONISTS FOR THE KAPPA OPIOID RECEPTOR | OPRK1, OPRM1, OPRD1 | OPRK1 1/4885CYP2D6 513/4885CYP3A4 462/4885 |
| US-11241415-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the κ opioid receptor | OPRM1, OPRK1, OPRD1 | OPRK1 2/4885CYP2D6 489/4885CYP3A4 423/4885 |
| US-10322107-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor | OPRK1, OPRM1, OPRD1 | OPRK1 1/4885CYP2D6 513/4885CYP3A4 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.